Market opportunity assessment in palliative care

Supporting a global medical device company to assess the opportunity for a new pain management product in palliative care

Scope:

EU4, UK, US

Therapy area:

Palliative care

Client:

Large global medical device company

The Challenge

The client was assessing target indications for the development of a new product to support with the management of pain

The client had identified palliative care as a potential target patient population, however required further information regarding the current treatment landscape for management of pain in end-of-life care (including price benchmarks), the evolving competitive landscape, the patient population size across Europe and the US, and the required product profile to align with key value drivers for prescribers/decision-makers

Project objectives

Define the current landscape for the management of pain in end-of-life care and how this varies across the EU4, UK and US

Highlight key unmet needs for the management of pain in end-of-life care, and likely value drivers for new treatment options

Define the number of patients per year treated in palliative care settings in the scope markets, to inform a commercial forecast of revenue potential for a new product considering likely price benchmarks and the addressable market

Define a target product profile to align with likely key value drivers for prescribers/decision makers in palliative care

Approach

A comprehensive landscape analysis was undertaken regarding the clinical guidance and associated literature for pain management in palliative care across the EU4, UK and US

Primary research discussions were undertaken with selected key stakeholders (including nursing staff) regarding the current treatment landscape and key value drivers for new product selection

Primary and secondary research insights were used to inform a detailed report, including a top line commercial forecast and target product profile for the new asset for the management of pain for end-of-life patients

VALUE DELIVERED

The client was provided with a detailed assessment of the landscape for the management of pain in end-of-life care and how this varies across the EU4, UK and US, the key value drivers for new treatment options, the optimal TPP to support access and uptake for a pain therapy in this patient group, and a top line commercial forecast based on estimated patient numbers and a price benchmark in line with current treatment options

Outputs were discussed in a workshop meeting with the client team, to inform the prioritisation of the lead indication for the asset in development

Related case studies

Full due-diligence process

Supporting a global medical device manufacturer with a full due-diligence assessment to support partner negotiations

Rapid multiple indication assessments

Rapid assessment of multiple ophthalmology orphan/non-orphan indications across the EU5 and the US

Rapid market opportunity assessment for an ATMP

Supporting a global pharmaceutical company with a market opportunity assessment to support commercial decision making

Cell and gene therapy landscape assessment

Global development landscape assessment of multiple ATMPs to support commercial decision making

Asset/brand planning for a cell therapy

Supporting a global pharmaceutical company to plan for the launch of a new cell therapy

Process development

Re-defining the opportunity assessment process for a global medical technology company